ACE Report Cover
Adhesive capsulitis: Pain & disability improved similarly with 20mg & 40mg corticosteroid
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
言語
Download Download Download
ダウンロード
Cite this Report Cite this Report Cite this Report
引用
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ お気に入り
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
言語
Download Download Download
ダウンロード
Cite this Report Cite this Report Cite this Report
引用
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ お気に入り

SHOULDER & ELBOW

Optimal dose of intra-articular corticosteroids for adhesive capsulitis: A randomized, triple-blind, placebo-controlled trial
High Impact
この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(10):33 Am J Sports Med. 2013 May;41(5):1133-9. doi: 10.1177/0363546513480475. Epub 2013 Mar 18

63 patients were randomized to determine the effect of varying doses of corticosteroid injections in the treatment of adhesive capsulitis. Participants were allocated to groups of high-dose triamcinolone (40mg), low-dose triamcinolone (20mg), or placebo (control) (1% lidocaine). Results after 12 weeks indicated that pain and disability were more significantly improved with both dosages of corticosteroid compared to control, but there was no difference between 20mg and 40mg triamcinolone. Corticosteroid injections also had a beneficial effect on passive range of motion in flexion, abduction, and internal rotation


出版資金提供の詳細 +
資金提供:
Non-Industry funded
スポンサー:
Research fund of Ajou University School of Medicine
コンフリクト:
None disclosed

バイアスのリスク

8/10

報告基準

19/20

脆弱性指数

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

はい = 1

不確実=0.5

無関係 = 0

いいえ = 0

報告基準評価では、著者が出版物内で試験の方法論的特徴や試験特性を報告する際の透明性を評価します。評価は以下の5つのカテゴリーに分類されます。

4/4

Randomization

3/4

Outcome Measurements

4/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

Fragility Indexは、重要な所見の解釈を助けるツールで、結果の強さの尺度を提供します。Fragility Indexは、その所見が有意でなくなるために、二項対立の結果に追加する必要がある連続した事象の数を表します。数値が小さいほど弱い所見を表し、数値が大きいほど強い所見を表します。

なぜ今この研究が必要なのですか?

Although intra-articular injections of corticosteroid have been and remain a mainstay in the treatment of adhesive capsulitis, there is little evidence available to guide clinician decision-making with respect to dosage. It has been suggested that the efficacy of steroid injections conforms to a dose-dependent relationship, with increasing dose leading to a more favourable outcome. Yet, simultaneously, the severity of cartilage damage linked to corticosteroid injection is also thought to be manifested through the same dose dependency. Therefore, it has become crucial to determine the optimal steroid dosage to use in the treatment of adhesive capsulitis.

主な研究課題は何ですか?

What was the comparative efficacy of 20mg triamcinolone acetonide, 40mg triamcinonlone acetonide, and placebo in adhesive capsulitis treatment?

研究の特徴 +
人口:
53 patients (aged 20-70) with stage 2 adhesive capsulitis (freezing stage as described by Hannafin and Chiaia). Other criteria for inclusion were restricted passive motion of greater than 30 degrees, pain lasting for at least one month, and average daily pain intensity of 3 points or greater on a 10cm visual analog scale.
介入:
High-dose steroid group: Patients received a single, utltrasound-guided intra-articular injection of 4mL of 10mg/mL triamcinolone acetonide and 1mL of 1% lidocaine to the glenohumeral joint from the posterior side of the shoulder (Mean age: 54.2; n=20) Low-dose steroid group: Patients received a single, ultrasound-guided intra-articular injection of 2mL of 10mg/mL triamcinolone acetonide and 3mL of 1% lidocaine to the glenohumeral joint from the posterior side of the shoulder (Mean age: 52.2; n=20)
比較:
Placebo group: Patients received a single, ultrasound-guided intra-articular injection of 5mL of 1% lidocaine to the glenohumeral joint from the posterior side of the shoulder (Mean age: 55.9; n=13, 11 completed follow-up)
アウトカム:
Primary outcome was measurement through the Shoulder Pain and Disability Index (SPADI). Secondary outcome measures included a visual analog scale (VAS 10-cm) for shoulder pain, and passive range of motion assessed with goniometer.
方法:
RCT, Triple-blind (participants, injection operator, and evaluator), Placebo-controlled, Dose-comparative
時間:
Evaluation was conducted 1, 3, 6, and 12 weeks postinjection

重要な知見は?

  • SPADI scores were reduced from 37.9 (SD 14.2) at baseline to 14.1 (SD 12.4) at 12 weeks in the high-dose group, 37.6 (SD 13.7) to 18.3 (SD 14.0) in the low-dose group, and 44.2 (SD 12.2) to 37.1 (SD 10.4) in the placebo group. Improvements in both the high-dose and low-dose steroid groups were significant compared to placebo (P<0.001 and P=0.001, respectively), although the difference between steroid groups was not significant (P=0.826).
  • Marked reductions in VAS pain were observed for the steroid groups; the high-dose group from 5.2 (SD 1.7) at baseline to 2.4 (SD 1.7) at 12 weeks, and the low-dose group from 4.9 (SD 1.3) to 2.4 (SD 1.3). The difference between these two group was not significant (P=0.999). Compared to placebo (reduction from 5.5 to 4.6), both steroid groups were observed to have a significantly greater reduction (High-dose: P<0.001; Low-dose: P=0.001).
  • Flexion, abduction, and internal rotation were significantly better in the high- and low-dose groups compared to placebo group (all P<0.005). The difference between the steroid groups was not significant for these measurements, however (P=0.485, 0.092, and 0.495, respectively).
  • The group-by-time interactions for extension and external rotation were not significant (P=0.331 and 0.094, respectively), however the group-by-time interactions for SPADI (P=0.007), VAS (P=0.004), flexion (P=0.024), abduction (P<0.001) and internal rotation (P=0.027) were all significant.
  • Facial flushing was observed in 3 high-dose participants and 1 low-dose participant. Dizziness due to a vasovagal reaction occurred in 1 patient of the placebo group and 1 in the low-dose group. These were the only complications reported.
最も覚えておくべきことは?

Injection of either 20mg or 40mg triamcinolone acetonide led to significantly reduced pain and disability compared to a control injection in the treatment of adhesive capsulitis. Furthermore, improved range of motion was observed with the corticosteroid injections. There were no differences in outcomes based on dose of triamcinolone acetonide received, and neither dose was associated with any serious adverse event.

それが私の患者ケアにどのように影響するか?

At 12 weeks post injection there appears to be no difference between a lower (20mg) and a higher dose (40mg) of triamcinolone. Given the lack of difference, a lower dose may be considered to avoid any potential complications that may exist with higher doses (even though the study found none). However, further investigation with a larger cohort of patients is required to confirm the efficacies of both high- and low-dose corticosteroid injections. Long-term effect of single injections should also be determined in future studies.

免責事項

このページに記載されている内容は、情報提供のみを目的としたものであり、専門的な医療アドバイス、診断、治療の代わりとなるものではありません。治療が必要な場合は、必ず医師の診断を仰ぐか、最寄りの救急外来を受診してください。このページに記載されている内容に関して個人が表明した意見、信念、見解は、OrthoEvidenceの意見、信念、見解を反映するものではありません。

0の4 月間無料記事のロック解除
今月の無料記事閲覧数が4件に達しました。

週1.99ドルからOrthoEvidenceにアクセスできます。

最新のエビデンスにアクセスしてください。いつでもキャンセルできます。
  • 整形外科における最新のインパクトのあるランダム化比較試験とシステマティックレビューの批判的評価
  • Journal of Bone and Joint Surgeryとのコラボレーション、国際的に著名な外科医へのインタビュー、整形外科ニュースやトピックに関する座談会など、OrthoEvidenceポッドキャストコンテンツへのアクセス
  • 週2回発行されるエビデンスに基づくニュースレター、The Pulseの購読。
Upgrade
Close Dialog
おかえりなさい
パスワードをお忘れですか?
今すぐ無料トライアルを開始

あなたのアカウントは
OrthoEvidenceへの無料アクセスが含まれます。


または
パスワードをお忘れですか?

または
Eメールをご確認ください

入力されたメールアドレスにアカウントが存在する場合、パスワードリセットのメールが送信されます。メールが届かない場合は、迷惑メールフォルダをご確認ください。

その他のサポート サポートチームまでご連絡ください。.

この機能を有効にするにはログインしてください

この機能にアクセスするには、有効なOrthoEvidenceアカウントにログインする必要があります。ログインするか、無料トライアルアカウントを作成してください。

ACEレポートを翻訳

OrthoEvidenceは、多言語でコンテンツにアクセスできるようにするため、第三者の翻訳サービスを利用しています。正確性を確保するためにあらゆる努力をしていますが、翻訳が必ずしも完璧ではない可能性があることにご注意ください。

引用方法 ACE Report

OrthoEvidence. Adhesive capsulitis: Pain & disability improved similarly with 20mg & 40mg corticosteroid. OE Journal. 2013;1(10):33. Available from: https://myorthoevidence.com/AceReport/Show/adhesive-capsulitis-pain-disability-improved-similarly-with-20mg-40mg-corticosteroid

引用のコピー
この機能を有効にするにはログインしてください

この機能にアクセスするには、有効なOrthoEvidenceアカウントにログインする必要があります。ログインするか、無料トライアルアカウントを作成してください。

プレミアム会員機能

この機能にアクセスするには、OrthoEvidenceのプレミアムアカウントにログインする必要があります。

共有 ACE Report